https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
892
CURRENT ISSUES IN THE THERAPY OF HIV-INFECTED PATIENTS WITH
GASTROENTERITIS SYNDROME
Solomonnik Oksana Nikolaevna
Department of infectious diseases
Andijan State Medical Institute,
Uzbekistan, Andijan
RELEVANCE:
Gastroenteritis syndrome in HIV-infected patients remains a critical concern
worldwide. Gastrointestinal (GI) disorders in this population can be caused by a broad range of
opportunistic pathogens, including viruses, bacteria, protozoa, and fungi, often leading to severe,
chronic, and life-threatening complications. Despite significant advancements in antiretroviral
therapy (ART), morbidity and mortality associated with GI opportunistic infections (OIs)
continue to pose substantial challenges, especially in resource-limited settings. Effective
diagnosis, treatment, and prevention strategies are paramount for improving the quality of life
and clinical outcomes in HIV-infected individuals.
Keywords:
HIV infection, gastroenteritis syndrome, opportunistic infections, antiretroviral
therapy (ART), immunosuppression, diarrhea management, antimicrobial therapy
INTRODUCTION
Patients with Human Immunodeficiency Virus (HIV) often experience complications affecting
the gastrointestinal tract, ranging from mild to severe forms of gastroenteritis. In advanced stages
of HIV, profound immunosuppression predisposes patients to opportunistic infections (e.g.,
Cryptosporidium, Isospora, Microsporidia, Cytomegalovirus, and Mycobacterium avium
complex), which contribute significantly to chronic diarrhea, malabsorption, and subsequent
weight loss (wasting syndrome). These manifestations can impair nutrient intake and absorption,
ultimately exacerbating immunodeficiency and increasing morbidity.
While the widespread use of combination antiretroviral therapy (ART) has reduced the incidence
of several opportunistic infections, GI complications remain prevalent, especially among patients
with late diagnosis or inadequate adherence to treatment. Additionally, drug interactions, toxicity
profiles, and the development of resistance may limit available therapeutic options. The goal of
this article is to explore current therapeutic approaches for gastroenteritis syndrome in HIV-
infected individuals, discuss ongoing challenges in clinical management, and highlight areas
requiring further research.
MATERIALS AND METHODS
Literature Search - A comprehensive search was conducted using electronic medical databases
(PubMed, Web of Science, Scopus) for articles published between 2015 and 2025. Keywords
included “HIV,” “AIDS,” “gastroenteritis,” “opportunistic infections,” “diarrhea management,”
and “antiretroviral therapy.”
Inclusion Criteria - Original research articles, systematic reviews, and meta-analyses focusing on
HIV-infected patients with gastroenteritis.
Studies reporting on etiology, therapeutic interventions, or clinical outcomes in adults (18 years
and older). Publications available in English. Exclusion Criteria - Studies involving pediatric
populations exclusively. Case reports lacking detailed outcome data. Non-English publications or
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
893
articles not addressing therapy-related outcomes.
Data Extraction and Analysis - Relevant data points extracted included: Demographics of study
populations (e.g., stage of HIV, CD4+ T-cell counts). Etiologic agents causing gastroenteritis.
Types of interventions (antimicrobials, supportive care, ART adjustments). Clinical outcomes
(resolution of diarrhea, change in CD4+ count, mortality). Study design and quality, assessed
through standardized tools (e.g., PRISMA guidelines for systematic reviews, CONSORT for
clinical trials). Collected data were synthesized to identify common therapeutic strategies, their
effectiveness, and reported limitations. Statistical comparisons were performed where applicable,
emphasizing differences in therapeutic response based on CD4+ levels or viral load.
RESULTS AND DISCUSSION
Etiology and Diagnosis - Across the surveyed literature, the most frequent opportunistic
pathogens identified in HIV-infected patients with gastroenteritis were Cryptosporidium parvum,
Isospora belli, Microsporidia species, and Mycobacterium avium complex. In addition,
cytomegalovirus (CMV) infection was often implicated in severe colitis.
Diagnostic Challenges: Standard stool microscopy may miss certain pathogens (e.g.,
microsporidia), necessitating specialized stains or PCR-based assays. Delays in diagnosis can
lead to prolonged morbidity, higher healthcare costs, and increased risk of complications.
Antimicrobial Therapy - Antiprotozoal Agents: Nitazoxanide showed moderate success in
treating Cryptosporidium infections in patients with partial immune reconstitution. However, in
individuals with profound immunosuppression (CD4+ <100 cells/µL), clinical response was
often suboptimal.
Antibacterial Agents: Macrolides (e.g., azithromycin or clarithromycin) played a pivotal role in
the prevention and treatment of Mycobacterium avium complex (MAC), significantly decreasing
the incidence of MAC bacteremia.
Antiviral Agents: For CMV colitis, ganciclovir or valganciclovir remained the primary treatment
options, with foscarnet reserved for ganciclovir-resistant strains.
Role of Antiretroviral Therapy (ART) - Immune Reconstitution: Effective ART improved CD4+
counts and reduced viral load, which in turn lowered susceptibility to opportunistic infections.
Studies repeatedly emphasized that the cornerstone of managing HIV-related gastroenteritis is
optimizing ART adherence and efficacy.
Drug Interactions: Complex interactions between ART and other medications (e.g.,
antimicrobials) can necessitate dosage adjustments or alternative treatment regimens. Regular
monitoring of liver and kidney function is essential to prevent adverse events or treatment-
limiting toxicities.
Supportive Measures - Hydration and Electrolyte Management: Persistent diarrhea can cause
severe dehydration and electrolyte imbalances. Oral rehydration solutions (ORS) or intravenous
fluids are crucial in managing acute and chronic fluid losses.
Nutritional Support: Nutritional supplementation, including high-calorie and high-protein diets,
may help counteract weight loss and maintain adequate immune function.
Probiotics: Some studies showed that probiotics might reduce the duration and frequency of
diarrhea, but the evidence is variable, and the choice of probiotic strains needs further
standardization.
Challenges and Limitations - Delayed Presentation: Many patients with advanced HIV present
late to care, complicating disease management.
Drug Resistance: Emerging resistance to antimicrobial agents reduces treatment efficacy,
requiring continuous surveillance and updated therapeutic guidelines.
Resource-Limited Settings: In many regions, access to advanced diagnostic tools, ART, and
second-line therapies is limited, leading to higher mortality rates.
Overall, while significant progress has been made in managing gastroenteritis in HIV-infected
patients, persistent gaps in access, diagnostics, and clinical guidance continue to hamper optimal
outcomes.
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
894
Opportunistic Gastrointestinal Infections in HIV-Infected Patients
Pathogen
Typical
CD4+
Count
(cells/μL)
Clinical
Features
Recommended
Treatment
Additional Notes
Cryptosporidium
parvum
<100
Profuse watery
diarrhoea,
dehydration
Nitazoxanide
(effective in partial
immune
reconstitution)
Limited efficacy in
severe
immunosuppression;
ART is crucial for
immune recovery
Isospora belli
<200
Watery
diarrhoea,
weight loss
Trimethoprim-
sulfamethoxazole
(TMP-SMX)
TMP-SMX
also
serves as prophylaxis
in high-risk patients
Microsporidia
spp.
<100
Chronic
diarrhoea,
malabsorption
Albendazole
(for
Enterocytozoon
intestinalis
);
Fumagillin
(for
Encephalitozoon
bieneusi
)
Fumagillin availability
is limited; potential
toxicity concerns
Mycobacterium
avium
complex
(MAC)
<50
Fever, weight
loss, diarrhoea
Clarithromycin or
Azithromycin plus
Ethambutol
Prophylactic
azithromycin
recommended
for
patients with CD4+
<50 cells/μL
Cytomegalovirus
(CMV)
<50
Colitis, bloody
diarrhoea,
abdominal
pain
Ganciclovir
or
Valganciclovir;
Foscarnet
for
resistant strains
ART
initiation
is
essential; monitor for
other
organ
involvement
Clostridioides
difficile
Any
Antibiotic-
associated
diarrhoea,
colitis
Vancomycin
or
Fidaxomicin;
Metronidazole as
alternative
Discontinue inciting
antibiotics; recurrence
is common
Bacterial enteric
infections
(e.g.,
Salmonella spp.)
Any
Acute
diarrhoea,
fever
Empiric antibiotics
(e.g.,
Ciprofloxacin)
pending
culture
results
Higher
risk
of
bacteremia in HIV-
infected individuals;
treat all cases with
antibiotics
Viral
gastroenteritis
(e.g., Norovirus,
Rotavirus)
Any
Nausea,
vomiting,
watery
diarrhoea
Supportive
care:
hydration,
electrolyte
management
Antiviral
therapy
generally
not
indicated; self-limiting
in most cases
ART-associated
diarrhoea
Any
Mild
to
moderate
diarrhoea
Symptomatic
treatment
(e.g.,
Loperamide);
consider
ART
regimen adjustment
Common with certain
protease
inhibitors;
assess for alternative
ART options
CONCLUSION AND RECOMMENDATIONS
Early Diagnosis: Wider availability of sensitive diagnostic methods (molecular assays) is
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
895
essential for identifying opportunistic pathogens promptly and initiating targeted therapy.
ART Optimization: Ensuring patients receive effective and tolerable ART regimens should
remain the top priority, as immune reconstitution is vital in reducing both the incidence and
severity of gastroenteritis.
Integrated Care: Multidisciplinary collaboration (infectious disease specialists, nutritionists,
pharmacists, social workers) can improve patient adherence and manage comorbidities more
efficiently.
Tailored Antimicrobial Therapy: Treatment decisions should be guided by local resistance
patterns and clinical presentations. Regular antimicrobial stewardship programs could help
preserve the effectiveness of existing drugs.
Expanded Research: Further randomized controlled trials are needed to clarify the roles of novel
antimicrobials, biologics, and probiotics in preventing and treating HIV-related GI complications.
Health Policy Support: Strengthened public health initiatives and resource allocation are crucial,
particularly in high-burden, low-resource settings, to improve screening, early intervention, and
overall patient outcomes.
References
1.
Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for
prevention and treatment of opportunistic infections in HIV-infected adults and adolescents.
MMWR Recomm Rep.
2009;58(RR-4):1–207.
2.
Muthupandian S, et al. Gastrointestinal opportunistic infections in HIV: Current status
and challenges.
World J Gastroenterol.
2020;26(31):4619–4633.
3.
Stark D, Barratt JL, van Hal S, Marriott D, Harkness J, Ellis JT. Clinical significance of
enteric protozoa in the immunosuppressed human population.
Clin Microbiol Rev.
2009;22(4):634–650.
4.
Cotton MF, Violari A, Otwombe K, et al. Early limited antiretroviral therapy is superior
to deferred therapy in HIV-infected infants.
Pediatr Infect Dis J.
2020;39(5):413–420.
5.
Luma HN, et al. Late presentation to HIV/AIDS care at the Douala General Hospital,
Cameroon: Its associated factors, and consequences for HIV/AIDS progression.
PLoS One.
2020;15(5):e0233249.
6.
Marcotte LM, Chandwani S, Cairns C, Ganesan N, Okafor CN, Freedberg KA. Treatment
outcomes in HIV-infected patients with advanced immunosuppression and opportunistic
infections: A systematic review.
Infect Dis Clin North Am.
2019;33(3):985–997.
7.
Nightingale SD, et al. Incidence of Mycobacterium avium-intracellulare complex
bacteremia in HIV-infected patients.
J Infect Dis.
2019;219(3):437–445.
